|Videos|June 17, 2015

Society for Immunotherapy in Cancer

Episodes in this series

Now Playing

EP. 1 Society for Immunotherapy in Cancer

EP. 2 ImmunoScore: Predictive and Prognostic?

EP. 3 Advances in Immuno-Oncology

EP. 4 Emerging Agents and Approaches in Immunotherapy

EP. 5 Patient Selection for Immunotherapies

EP. 6 Identifying and Managing Toxicities of Immunotherapy

EP. 7 Biomarkers and Immunotherapy

EP. 8 Phase I Immunotherapy Trials

EP. 9 Clinical Trial Design for Immunotherapy

EP. 10 History and Evolution of Immuno-oncology

Stay up to date on the most recent and practice-changing oncology data

Related to this article

HNSCC | Image Credit: © G.Go - stock.adobe.com

October 4th, 2026

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC

The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.

Perioperative Durvalumab Plus EV in MIBC | Image Credit: © Adin - stock.adobe.com

September 25th, 2026

FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC

FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.

Bladder Cancer | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

September 18th, 2026

CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC

The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.